MAPK10 and Alzheimer disease: Studies on post-mortem brain samples have shown a greater expression of phosphorylated JNK3 in AD patients in addition to the presence of (Aβ) [7], while further studies have identified JNK3 to be highly expressed and activated in brain tissue and cerebrospinal fluid in patients with AD, in addition to being statistically correlated with the level of cognitive decline [8,9].